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Aminoglycoside (AG), which was first discovered in 
1944, is widely used in treating severe Gram-negative 
bacterial infections (1). Gentamicin, kanamycin, amikacin 
and neomycin are the major AGs used nowadays, and 
vancomycin is the drug of choice for methicillin-resistant 
Staphylococcus aureus (MRSA) infection. Although other 
antibiotics can also target Gram-negative bacteria such 
as penicillins and cephalosporins, AGs remain to be the 
popular choice because of their economical and clinical 
advantages including low cost, rapid bactericidal activity 
and low incidences of resistance (2). However, the adverse 
effects of reversible nephrotoxicity and irreversible 
ototoxicity limit their use to short term therapy (3,4). 
Precaution is needed for treating senior patients who are 
prone to have hearing, vestibular and renal dysfunctions. 
Identification of the predisposing factors of such toxicities 
will allow us to maximize the benefit of using AGs and 
greatly improve the therapeutic outcome. 
The link of ototoxicity, which is manifested as tinnitus 
or severe permanent hearing loss, with AGs was first 
determined in 1984 from three prospective, randomized, 
double-blind clinical trials of gentamicin, tobramycin and 
amikacin (5). In the United States, 2% to 5% of patients 
receiving AGs develop hearing loss (6,7). The longer 
duration of treatment and the higher dose being used, the 
higher susceptibility of developing ototoxicity. AG can be 
rapidly taken up by cochlear hair cells following systemic 
administration via endocytosis(8) or mechanoelectrical 
transduction channels at their apical membranes (9). The 
accumulation of AG in cochlear hair cells leads to increased 
production of reactive oxygen species (ROS) and activation 
of stress kinases and caspases, resulting in apoptosis of these 
cells (10). Older age, renal dysfunction, mitochondrial 
dysfunction and genetic factors are the known predisposing 
factors of the ototoxicity; however, the related mechanisms 
remain unclear (7,11,12). In the early studies in 1984, the 
researchers had already found that patients with auditory 
toxicity underwent AG therapy for a longer period and 
were more likely to be bacteremic (7). Why does AG-
induced ototoxicity depend more on the duration of 
treatment rather than the plasma concentration of AG? Is 
the ototoxicity related to the endotoxin level as AGs are 
mainly indicated for Gram-negative bacterial infections? A 
recent study conducted by Koo et al. has given us insight in 
answering these questions (13). 
By tracing fluorescently-tagged gentamicin (GTTR) in 
the LPS-induced endotoxemia model, Koo et al. found that 
the augmented accumulation of AG in cochlear walls and 
different cell types in the ear was proportional to the dose of 
LPS administered into mice, indicating LPS can potentiate 
the uptake and trafficking of AG across the blood-
labyrinth barrier (BLB). The auditory toxicity is associated 
with the concentration of AG in the inner ear (14). 
In this study, low-dose LPS injection was shown to enhance 
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the accumulation of GTTR in cochlear but not in serum, 
which is congruent with the earlier finding that the 
ototoxicity was independent of plasma AG concentration (7). 
Administration of LPS acutely increased the expressions 
of pro-inflammatory molecules in both cochleae and 
circulation but the expressions of interleukin 1-beta (IL-1β) 
and interleulin-10 (IL-10) were induced in circulation only. 
The LPS-induced inflammation in cochleae sustained till 
24 hours after the initial LPS injection when the plasma 
concentrations of inflammatory proteins had already 
subsided. LPS can induce pro-inflammatory responses 
through activating toll-like receptor (TLR) pathways, and 
the observed potentiating effect of LPS on AG-induced 
ototoxicity was TLR4 dependent. LPS failed to elicit 
inflammatory response in TLR4-hyporesponsive C3H/
HeJ mice, and concurrently the accumulation and uptake 
of AG were also reduced. More importantly, Koo et al. 
discovered that repeated low-dose LPS administration 
exacerbated AG-induced auditory brainstem response (ABR) 
threshold shifts, and acute LPS-induced endotoxemia did 
not modulate auditory threshold, suggesting the integrity 
of BLB remains intact in LPS-aggravated ototoxicity of 
AG. Low-dose LPS was shown to dilate the basal strial 
capillaries and decrease vasoconstrictive serotonin in serum, 
without affecting the permeability of BLB. It is noteworthy 
to investigate whether restoration of serotonin level or local 
application of vasoconstrictor can alleviate the endotoxemia-
aggravated ototoxicity of AG. In addition, as decreased 
cochlear expression of proinflammatory molecules 
together with attenuated capillary dilation and reduced AG 
accumulation were observed in hyporesponsive TLR4 mice 
injected with LPS, local antagonism of TLR4 signaling 
(e.g., eritoran), or removal of LPS (e.g., polymixin B) 
may serve as a therapeutic option to prevent or treat AG-
induced auditory damage (Figure 1). 
Majori ty  of  s tudies  on AG-related ototoxic i ty 
often use healthy and uninfected animals, where the 
pathophysiological conditions are substantially different 
from patients with Gram-negative bacterial infection. In the 
infected patients, adaptive inflammatory response against 
bacterial infection is autonomous, and release of endotoxin 
due to the bacteriolytic effect of antibiotics contributes to 
endotoxemia. This study by Koo et al. highlights that this 
inevitable condition in patients can indeed aggravate AG-
induced auditory toxicity. Their findings not only suggest 
the molecular mechanisms that provide insight in developing 
preventive or treatment options for ototoxicity, but also 
help to identify individuals that are susceptive to such 
adverse effect of AG. Patients with higher inflammatory 
status due to other conditions should avoid using AGs for 
Gram-negative infections. Metabolic endotoxemia, which is 
defined as a two- or three- fold increase of serum LPS level, 
is often observed in obese individuals (8). High-fat diet can 
increase intestinal permeability which allows the leaking of 
bacterial products such as LPS from the intestinal lumen 
into the bloodstream, consequently causing metabolic 
endotoxemia (8). Considering the growing prevalence 
of obesity, special attention is required for treating these 
patients. Furthermore, patients with autoimmune diseases 
such as colitis may also have weakened gut barrier and 
certain degree of endotoxemia (15). For all these conditions, 
clinicians may need to seek other options for treating 
Gram-negative bacterial infections. 
AGs remain as the drug of choice for most of the Gram-
Figure 1 Endotoxemic conditions aggravate AG-induced 
ototoxicity. Disease states such as bacterial infection, obesity, 
autoimmune diseases are associated with the increased circulating 
LPS level. LPS binds to TLR4 resulting in augmented production 
of pro-inflammatory molecules. The increased pro-inflammatory 
proteins promote the dilation of the strial capillaries, which 
further increases the accumulation of AG and worsens the auditory 
toxicity.
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negative bacterial infections because of their effectiveness; 
however, the concern of irreversible ototoxicity limits their 
use. In this study, Koo et al. emphasize the important effect 
of endotoxemia in developing of auditory toxicity, which 
provides an additional guideline to weighing the balance 
between risk and benefit of using AGs. It would make the 
best use of our existing effective antibiotics, and this is 
particularly important as very few new antibiotics have been 
identified in recent decades and resistance of antibiotics 
remains to be a major challenge for treating infectious 
diseases.
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